EE Impact

PAREXEL

USA · Pharma & Healthcare

LeaveRussia detail: Scaling Back

Scaling back

PAREXEL International is a global provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today.

Status last verified 03/08/2026Source checked 10/06/2025Company website ↗LeaveRussia profile ↗

Business in Russia

PAREXEL have 6,000+ staff, with 30+ offices across the region, early phase clinics located in Berlin and London, and clinical trial supplies and logistics depots located in Germany and Russia.

Decision trail

Decision date 25/08/2022 · Reference ↗

Received revenues in Russia in 2021-2024, there is no any official announcement. Revenue decreased in 2024 vs 2023 by more than -20%.

Local stats (LeaveRussia)

Assets(RF), mln.USD
11
Capital(RF), mln.USD
9
Revenue(RF), mln.USD
6
Staff(RF), 2021
294
Taxes(RF), mln.USD
3

Status history since 2022

  1. 03/08/2026 scaling back · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.